This work, describing siRNA targeting FXIII-B (siFXIIIB), is the first pharmacologic approach for long-acting, reversible, and targeted decrease of FXIII-A activity in vivo. It enables the study of FXIII in a wide range of disease models, including in animals not amenable to genetic FXIII knockout. FXIII is considered a therapeutic target for preventing thrombosis, and siFXIIIB overcomes limitations of current antithrombics and thrombolytics by specifically enhancing endogenous fibrinolysis.
Read More
Genome British Columbia (Genome BC) today announced the appointment of Dr. Federica Di Palma as Chief Scientific Officer (CSO) & Vice President, Sectors. She brings over 20 years of international experience in science, technology and innovation with an emphasis on understanding complex biological systems. Dr. Di Palma’s deep understanding of genomics and strategic expertise will make her an essential member…
Read More
AbCellera today announced that LY-CoV555, a human antibody discovered by AbCellera in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and co-developed with Eli Lilly and Company (Lilly) as a potential treatment and prophylaxis for COVID-19, has progressed to Phase 3 clinical trials. A first-of-its-kind, the Lilly-sponsored trial will use customized mobile research…
Read More
In some Huntington disease (HD) patients, the “loss of interruption” (LOI) variant eliminates an interrupting codon in the HTT CAG-repeat tract, which causes earlier age of onset (AOO). The magnitude of this effect is uncertain, since previous studies included few LOI carriers, and the variant also causes CAG size misestimation. We developed a rapid LOI detection screen, enabling unbiased frequency estimation among…
Read More
In her most recent Forward Thinking post, Dr. Bev Holmes unpacked what it means to be a responsible and responsive health research funder during a pandemic. With my first Forward Thinking post in my new role as Vice President, Research for MSFHR, I reflect on what success looks like for responsive and responsible research funding. Forward Thinking is MSFHR’s blog focusing on what it takes…
Read More

Cell Recycling Mechanism May Inform Breast Cancer Patient Prognosis

Autophagy is a highly regulated process in the cell that removes or recycles unnecessary or dysfunctional molecules, breaking them down and reusing them to assemble new cellular structures. In cancer, it has been shown to contribute to both disease suppression and progression depending on a number of factors, including the stage of the disease. In advanced cancer, it enhances tumour cell survival and…
Read More
To say that the past few months have been “challenging” would be a hefty understatement. Amid a global pandemic, countless aspects of our lives have undergone a radical shift: adapting to physical distancing, working from home, as well as dealing with the financial, social, and emotional toll of COVID-19. Everyday activities and long-awaited special occasions alike have either gone virtual…
Read More
Ovarian cancer, the fifth most common cause of cancer death in Canadian women, has several subtypes, one of which is Adult Granulosa Cell Tumours (AGCT), the subtype accounting for two to five per cent of ovarian cancer cases. In 2009, in a landmark study published in The New England Journal of Medicine, BC Cancer’s Dr. David Huntsman collaborated with researchers at the GSC to…
Read More
Autophagy is a highly regulated process in the cell that removes or recycles unnecessary or dysfunctional molecules, breaking them down and reusing them to assemble new cellular structures. In cancer, it has been shown to contribute to both disease suppression and progression depending on a number of factors, including the stage of the disease. In advanced cancer, it enhances tumour cell survival and…
Read More